Dr. Sandeep Menon is Chief Development Officer at Alnylam Pharmaceuticals, where he leads a global team overseeing end-to-end development across all therapeutic areas. Before Alnylam, he was Senior VP and Head of Early Clinical Development at Pfizer, overseeing Pfizer’s entire pipeline from IND through Phase 2b. During his 14 years at Pfizer, Dr. Menon’s leadership was key in turning R&D productivity around, achieving a Phase II success rate of over 50%. His team played pivotal roles in Litfulo, CIBINQO, gene therapies for hemophilia and Duchenne’s muscular dystrophy, Elrexfio, GLP-1, TL1A and breast/prostate cancer programs. His team also co-led rapid development of Paxlovid, from first-in-human to emergency-use authorization in 9 months. He was also Chief Scientific Officer for AI and Digital Sciences, overseeing the cutting-edge Pfizer Innovation and Research (PfIRE) Lab. Before Pfizer, he held leadership roles at Biogen Idec and Averion (now ICON). And before that, he practiced family medicine as Resident Medical Officer in Mumbai, India. Dr. Menon received his MD from Karnataka University, MPH and PhD in Biostatistics from Boston University, and MS in Translational Pharmacology from OSU. He is adjunct faculty at Boston University, Tufts, and IIM, and has published 60+ scientific papers and co-authored/co-edited eight books.